A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Public ClinicalTrials.gov record NCT07218146. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
Study identification
- NCT ID
- NCT07218146
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 480 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2025
- Primary completion
- Jun 29, 2028
- Completion
- Nov 29, 2028
- Last update posted
- May 13, 2026
2025 – 2028
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Zai Lab Site 02037 | Aurora | Colorado | 80045 | Recruiting |
| Zai Lab Site 02030 | New Haven | Connecticut | 06519 | Recruiting |
| Zai Lab Site 02045 | Clermont | Florida | 34711 | Recruiting |
| Zai Lab Site 02031 | Orange City | Florida | 32763 | Recruiting |
| Zai Lab Site 02020 | Rockledge | Florida | 32955 | Recruiting |
| Zai Lab Site 02026 | Sarasota | Florida | 34232 | Recruiting |
| Zai Lab Site 02052 | St. Petersburg | Florida | 33701-4553 | Recruiting |
| Zai Lab Site 02051 | West Palm Beach | Florida | 33401 | Recruiting |
| Zai Lab Site 02021 | Peoria | Illinois | 61615 | Recruiting |
| Zai Lab Site 02049 | Peoria | Illinois | 61637 | Recruiting |
| Zai Lab Site 02038 | Iowa City | Iowa | 52242 | Recruiting |
| Zai Lab Site 02041 | Louisville | Kentucky | 40202 | Recruiting |
| Zai Lab Site 02003 | Bethesda | Maryland | 20817 | Recruiting |
| Zai Lab Site 02022 | Silver Spring | Maryland | 20904 | Recruiting |
| Zai Lab Site 02010 | Detroit | Michigan | 48202 | Recruiting |
| Zai Lab Site 02023 | Columbia | Missouri | 65201 | Recruiting |
| Zai Lab Site 02009 | St Louis | Missouri | 63128 | Recruiting |
| Zai Lab Site 02040 | The Bronx | New York | 10461 | Recruiting |
| Zai Lab Site 02024 | Cleveland | Ohio | 44106 | Recruiting |
| Zai Lab Site 02035 | Broomall | Pennsylvania | 19008 | Recruiting |
| Zai Lab Site 02019 | Media | Pennsylvania | 19063 | Recruiting |
| Zai Lab Site 02008 | Pittsburgh | Pennsylvania | 15212 | Recruiting |
| Zai Lab Site 02029 | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Zai Lab Site 02036 | Nashville | Tennessee | 37203 | Recruiting |
| Zai Lab Site 02025 | Austin | Texas | 78745 | Recruiting |
| Zai Lab Site 02046 | Dallas | Texas | 75390-9020 | Recruiting |
| Zai Lab Site 02025 | Odessa | Texas | 79761 | Recruiting |
| Zai Lab Site 02006 | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
Recently updated Small-cell Lung Cancer trials
Other public records listing Small-cell Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT01064466: Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms Active, not recruiting
- NCT07783477: A Study of Armored CAR T Cells in People With Cancer Not yet recruiting
- NCT07778316: Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) Recruiting
- NCT07365241: A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer Recruiting
- NCT07707895: DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers Not yet recruiting
- NCT06931626: Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07218146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07218146 live on ClinicalTrials.gov.